10/14/2020|Press releasesRostock, October 14th, 2020, SensID and Noscendo combine forces to develop a contamination-free reference material with known human DNA quantity and virus status for clinical system validation. The reference material is developed by SensID and tested by Noscendo to be positive for standard microbial DNA and completely free of contaminating microbial DNA. The reference materials will serve as process controls to ensure highest process quality and validity for patient samples. In hospitals in Germany, sepsis accounts for a major portion of fatal infections. Adequate treatment of patients with anti-infectives is crucial,…

05/05/2020|Press releases Ennigerloh & Rostock, May 5th, 2020 – SensID GmbH is a leading specialist in quality diagnostics and offers a SARS-CoV-2 immunity testing service to all interested companies (and their staff) as part of an initiative of the State of Mecklenburg-Western Pomerania (to cope with the economic consequences of the pandemic). Rottendorf Pharma, with its headquarters in Ennigerloh, Germany, and with more than 1100 employees, is one of the leading contract development and manufacturing organizations (CDMO) for solid dosage forms for the international pharmaceutical industry. “The approach and the competence…

04/21/2020|Press releasesRostock, 7th of April 2020  SensID GmbH, a Germany based provider of controls and reference materials for clinical genomics, today announces that it has developed a set of controls for the US FDA approved and CE-IVD marked therascreen PIK3CA RGQ PCR Kits from QIAGEN.  The CE-IVD therascreen PIK3CA RGQ PCR Kit was launched in Europe in February 2020 as an aid to the identification of activating PIK3CA mutations in samples of either FFPE tumour tissue or blood plasma taken from patients with advanced breast cancer. The US IVD Kit was approved by the FDA in 2019 and has been successfully commercialized in the U.S. as a companion diagnostic test for the Novartis drug PIQRAY® (alpelisib).  As more stringent regulations such as…

05/14/2019|Press releases SensID GmbH, a leading specialist in the development and manufacturing of high quality reference standards for molecular diagnostics, and TATAA Biocenter AB, a pioneer within the industry and leading provider of high quality molecular analyses announced today the signing of a distribution agreement. SensID gives TATAA full access to its continuously growing product portfolio for Molecular Diagnostics, and TATAA will represent SensID in Sweden, Denmark, Norway, Finland, Czech and Slovak Republics. “With its strong focus on reference materials for Molecular Diagnostics, SensID is a perfect solution provider for…